著者
大城 吉則 安次嶺 聡 木村 隆 宮城 亮太 玉城 由光 仲西 昌太郎 松村 英理 大城 琢磨 宮里 実 呉屋 真人 斎藤 誠一
出版者
一般社団法人 日本移植学会
雑誌
移植 (ISSN:05787947)
巻号頁・発行日
vol.51, no.1, pp.40-47, 2016

【Objective】Good long-term kidney graft function and graft survival depend on multiple factors. This study aimed to assess the impact of donor and recipient clinical factors on 20-year graft survival after kidney transplantation (KT).<br/>【Material and Methods】From 1987-1994, twenty-five KTs (14 living and 11 deceased donors) were performed at Ryukyu University Hospital, and 24 of these cases were followed for more than 20 years after the KTs and reviewed. Ten patients had 20 years of graft survival, and 14 experienced graft failure for some reason within 20 years after KTs. Retrospective analyses were performed to elucidate the difference in donor and recipient factors among these patients.<br/>【Results】The death censored graft survival rates at 5, 10, 15, and 20 years were 92.0%, 83.0%, 67.0%, and 67.0% in living-donor KTs and 73.0%, 62.0%, 62.0%, and 31.0% in deceased-donor KTs, respectively. The overall graft survival rates at 5, 10, 15, and 20 years were 85.0%, 77.0%, 62.0%, and 54.0% in living-donor KTs and 63.0%, 55.0%, 45.0%, and 27.0% in deceased-donor KTs, respectively. Comparison of clinical factors between the ≥ 20-year graft survivor group (10 cases) and <20-year graft survivor group (14 cases) revealed no differences in, for example, recipient age, duration of dialysis, donor age, donor type, number of human leukocyte antigen mismatches, and occurrence of acute rejections within 1 year of KTs. However, among 13 cases of living-donor KTs, the overall graft survivals after KTs from donors older than 50 years were worse than those after KTs from donors younger than 50 years. Also, the death-censored graft survivals after KTs from donors older than 60 years were worse than those after KTs from donors younger than 60 years. Moreover, graft survivals after KTs from maternal donors were worse than those after KTs from nonmaternal living donors, and there were no 20-year graft survivors after KTs from maternal donors.<br/>【Conclusion】Our results suggest that the principal risk factors associated with <20-year graft survival after living-donor KTs are the presence of donors older than 50 or 60 years and a maternal donor.
著者
塚田 敬義
出版者
一般社団法人 日本移植学会
雑誌
移植 (ISSN:05787947)
巻号頁・発行日
vol.50, no.1, pp.031-036, 2015-03-10 (Released:2015-03-31)
参考文献数
24

There is a kidney that provides less current from cardiac arrest donors. One of the causes is considered to be in the excessively heavy burden of hospital staffs. In the future, it will become necessary to examine the policy to increase organ donations. Disability injuries to further joining by living donors will also be required.
著者
日本小腸移植研究会
出版者
一般社団法人 日本移植学会
雑誌
移植 (ISSN:05787947)
巻号頁・発行日
vol.49, no.2-3, pp.298-302, 2014-06-10 (Released:2014-07-18)

Twenty-five intestinal transplants were performed since 1996 in 5 institutions. There were 13 deceased donor and 12 living related donor transplants. Primary causes of intestinal transplants were short gut syndrome (n=9), intestinal mobility function disorder (n=12), others (n=1) and re- transplantation (n=3). 1 year patient survival was 86%, and 10-year patient survival was 66%. They were considered to be excellent results for a standard therapeutic option for intestinal failure if patients fail to maintain total parental nutrition.
著者
日本膵・膵島移植研究会膵島移植班
出版者
一般社団法人 日本移植学会
雑誌
移植 (ISSN:05787947)
巻号頁・発行日
vol.49, no.2-3, pp.292-297, 2014-06-10 (Released:2014-07-18)
参考文献数
6

Islet transplantation can relieve glucose instability and problems with hypoglycemia while the graft is functioning. However, the long-term results of islet transplantation pointed to the need for progress improving islet graft function. We started the phase II clinical trial with type 1 diabetes patients for islet transplantation using both brain-dead donors and DCD to evaluate ATG induction and TNF inhibition protocol. Primary endpoints are the proportion of subjects with HbA1c<7.4% and who are free of severe hypoglycemic events one years after the first islet cell infusion. This trial would play a critical role in establishing islet transplantation in Japan.